Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2008
Context: The filing serves as a Regulation FD disclosure to announce performance data regarding the Company's OraQuick ADVANCE Rapid HIV-1/2 Antibody Test.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the disclosure of product performance data rather than financial results.
Material Changes
Product Performance Disclosure: On June 16, 2008, the Company issued a press release (attached as Exhibit 99.1) announcing performance data for the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. No other material changes to financial position or operations are detailed in the text of this filing.
Guidance, Outlook, and Risks
- Management Commentary: The filing references a press release containing performance data but does not include specific management commentary, future guidance, or outlook within the body of the 8-K text.
- Legal Disclaimers: The Company explicitly states that the information and attached exhibit are not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and are not subject to the liabilities of that section.
- Update Obligation: The Company undertakes no duty or obligation to publicly update or revise the information contained in this Current Report or the attached exhibit.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated June 16, 2008) for specific performance metrics of the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test.
- Verify if the performance data impacts regulatory status or market expectations for the product.
- Note that the Company has disclaimed any obligation to update this specific information in the future.